Metanalysis shows patients w/ psoriasis have signif. higher risk (2-2.5 fold) of metabolic syndrome compared to the general population, RA or spondylitis patients. Comparing PsO to PsA there is no difference (PsA also has a high riskof MetS). https://t.co/gO3IomfP53 https://t.co/Ov2UHV2mN6